𝔖 Bobbio Scriptorium
✦   LIBER   ✦

New therapies for Parkinson's disease

✍ Scribed by Ruth Djaldetti; Eldad Melamed

Publisher
Springer
Year
2001
Tongue
English
Weight
191 KB
Volume
248
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

New developments in surgical therapy for
New developments in surgical therapy for Parkinson's disease
πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 157 KB

F r a n c e . Surgical methods are still of interest when levodopa therapy fails. High frequency stimulation has similar effects and is safer than destruction in several basal ganglia, such as Ventral Intermediate Thalamus (Vim), Subthalamic Nucleus (STN) and Globus Pallidus Internus (GPi) has trigg

Mitochondrial therapies for Parkinson's
Mitochondrial therapies for Parkinson's disease
✍ Bobby Thomas; M. Flint Beal πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 73 KB πŸ‘ 1 views

## Abstract Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center sta

Systematic review of paramedical therapi
Systematic review of paramedical therapies for Parkinson's disease
✍ Katherine H.O. Deane; Caroline Ellis-Hill; Diana Jones; Renata Whurr; Yoav Ben-S πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 84 KB

## Abstract We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews. All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all

Neuroprotective Therapy for Parkinson's
Neuroprotective Therapy for Parkinson's disease
✍ I.Shoulson and the Parkinson Study Group πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 1 views

In the context of degenerative disorders of the basal ganglia, neuroprotective therapy refers to interventions that preserve the integrity and function of vulnerable neurons and thereby slow or halt clinical decline. Decoppering therapy for Wilson's disease is the only established neuroprotective th

Milacemide therapy for Parkinson's disea
Milacemide therapy for Parkinson's disease
✍ M. E. Giuffra; V. H. Sethy; T. L. Davis; M. M. Mouradian; Dr. T. N. Chase πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 303 KB

## Abstract The clinical effects of central glutamatergic stimulation by the glycine prodrug milacemide were studied in six patients with Parkinson's disease under double‐blind, placebo‐controlled conditions. When administered as monotherapy at a single oral dose of 1,200 mg, the drug increased ove